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The National Cancer Institute (NCI) sponsored the NCI Thyroid
Fine Needle Aspiration (FNA) State of the Science Conference
on October 22–23, 2007 in Bethesda, MD. The 2-day meeting
was accompanied by a permanent informational Web site and
several on-line discussion periods between May 1 and December
15, 2007 (http://thyroidfna.cancer.gov). This document addresses
follow-up procedures and therapeutic options for suggested
diagnostic categories. Follow-up options for ‘‘nondiagnostic’’
and ‘‘benign’’ thyroid aspirates are given. The value of ultra-
sound examination in the follow-up of ‘‘nondiagnostic’’ and
‘‘benign’’ thyroid aspirates is discussed. Ultrasound findings
requiring reaspiration or surgical resection are described as are
the timing and length of clinical and ultrasonographic surveil-
lance for cytologically ‘‘benign’’ nodules. Options for surgical
intervention are given for the diagnostic categories of ‘‘atypical/
borderline,’’ ‘‘follicular neoplasm,’’ ‘‘suspicious for malignancy’’
and ‘‘malignant’’ (http://thyroidfna.cancer.gov/ pages/info/agenda/).
Diagn. Cytopathol. 2008;36:442–448. ' 2008 Wiley-Liss, Inc.{
Key Words: thyroid; fine-needle aspiration; follow-up; ultra-
sound; nondiagnostic; indeterminate; follicular neoplasm; papil-
lary carcinoma
The authors of this document are members of Committee
VI. The charge of this committee was to evaluate possible
post-FNA testing and treatment options. This area was
further subdivided into discussion topics, designated A–F
in the discussion that follows (http://thyroidfna.cancer.
gov/pages/info/agenda/). This is a summary of the
‘‘Review and Conclusions’’ of the subject matter that this
committee analyzed based on several parameters: litera-
ture reviews limited to English language publications dat-
ing back to 1995 using PubMed as the search engine with
key words determined by the committee members; online
forum discussions (http://thyroidfna.cancer.gov/forums/
default.aspx), and formal interdisciplinary discussions
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held at the October 2007 conference. This is not a ‘‘stand-
ards of practice’’ guideline, nor is it endorsed as such by
the National Cancer Institute.
The success of fine-needle aspiration (FNA) in the
evaluation of thyroid nodules depends on the utilization
of reproducible diagnostic categories associated with
widely accepted follow-up and therapeutic strategies.
Diagnostic categories should result in similar follow-up
and management strategies among institutions and
physicians managing and treating patients with thyroid
nodules. This document addresses management strat-
egies associated with the diagnostic categories desig-
nated as ‘‘nondiagnostic,’’ ‘‘benign,’’ ‘‘atypical/border-
line,’’ ‘‘follicular neoplasm,’’ ‘‘suspicious for malig-
nancy,’’ and ‘‘malignant.’’ These categories are further
discussed in the accompanying article by Baloch et al.1
Figure 1 shows a potential approach to management of
thyroid nodules.
Follow-Up of ‘‘Nondiagnostic’’ FNA Results
A universally accepted approach to ‘‘nondiagnostic’’ thy-
roid fine-needle aspirates (FNAs) remains lacking, but the
American Thyroid Association (ATA) has proposed a set
of strategies that are currently widely accepted.2 The fol-
lowing strategy for post-FNA testing and treatment is
based partially on the ATA recommendations as well as
the guidelines developed by The American Association of
Clinical Endocrinologists with The American Association
of Endocrine Surgeons,3 The British Thyroid Association
in conjunction with The Royal College of Physicians4 and
The Comprehensive Cancer Network5 along with pro-
posals discussed at the NCI State of the Science Confer-
ence in October of 2007.
Nondiagnostic aspirates may be due to the qualitative
or quantitative nature of the material received. Clearly,
aspirates distorted by abundant blood or otherwise techni-
cally compromised because of smearing, fixation, or stain-
ing artifacts are nondiagnostic. The quantitative aspect of
specimen adequacy is more controversial. It is clear that
smear cellularity depends on several factors including the
aspirator’s skill and the intrinsic nature of the thyroid
nodule.6 The cellularity is most germane for adequacy
assessment of cystic and partially cystic thyroid nodules.
All thyroid cysts should be completely drained and the
Fig. 1. A potential post-FNA protocol for follow-up and treatment of a thyroid nodule.
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cyst wall should be sampled. Specimens obtained from
cystic nodules may yield two types of specimens. One in
which the material is composed of pure colloid without
an epithelial component. The second type is watery fluid
in which are dispersed a number of histiocytes and histio-
cyte-like cells with varying degrees of nuclear atypia.
Aspirates composed of pure colloid and lacking a cellular
component can be considered benign rather than ‘‘non-
diagnostic.’’ Aspirates of cysts containing blood and his-
tiocytes, but no epithelial cells need correlation with ultra-
sound findings.7 If ultrasound examination discloses suspi-
cious areas, these aspirates should be considered
‘‘nondiagnostic.’’ Cystic lesions yielding ‘‘nondiagnostic’’
aspirates should undergo repeat FNA either with or with-
out ultrasound guidance. (For a further discussion of the
indications for repeat FNA, please see the accompanying
article in this issue by Cibas et al.)8 When repeat FNA
yields a ‘‘nondiagnostic’’ aspirate, close clinical follow-up
or surgery has been recommended by the ATA. Solitary
nodules that are repeatedly ‘‘nondiagnostic’’ on fine-nee-
dle aspiration have an unknown risk of malignancy, but it
is probably between 5 and 10%.9 The choice of clinical
or surgical follow-up in nodules with repetitively ‘‘non-
diagnostic’’ results is left to the discretion of the clinician.
Many cystic nodules contain only central colloid sur-
rounded by a thin rim of follicular epithelium, and even
when drained and the cyst wall sampled, little or no fol-
licular epithelium is obtained. These cysts are at very low
risk for harboring malignancy and their precise follow-up
has been controversial.
Surgical resection of these nodules will result in a high
percentage of nonneoplastic specimens which do not
require surgery for therapeutic reasons. Hence, many
authors have recommended that management of these
cysts in reliable patients is best achieved by clinical/non-
surgical follow-up. Other authors point to the low, but
real incidence of cystic papillary carcinoma in these
cystic nodules. Based on this low incidence of carcinoma,
they recommend surgical resection of the nodule follow-
ing two ‘‘nondiagnostic’’ aspirations. Timing of repeat
FNA has not been established, but 6–18 months appears
to be a reasonable interval.
The ATA recommends that solid nodules associated
with a ‘‘nondiagnostic’’ smear should be reaspirated with
ultrasound guidance, and if repeat aspirates remain ‘‘non-
diagnostic,’’ surgery should be strongly considered.2
Repeat aspirates should be performed with the assistance
of cytopathology whenever possible.10 Some authors rec-
ommend that solid nodules less than 1 cm in size and
associated with a ‘‘nondiagnostic’’ repeat aspirate should
be followed by ultrasound and only undergo surgical resec-
tion if enlargement is documented on repeat ultrasound ex-
amination.7 For further discussion of this topic, please see
the accompanying article in this issue by Cibas et al.8
Conclusions
1. Cystic lesions with an initial ‘‘nondiagnostic’’ aspi-
rate should undergo a repeat FNA if ultrasound ex-
amination demonstrates suspicious areas. The repeat
FNA should be under ultrasound guidance, and
when possible, intraprocedural review of the aspi-
rated material by a cytopathologist is optimal. The
cyst should be completely drained and the cyst wall
sampled. When repeat FNA yields ‘‘nondiagnostic’’
material, correlation with family history and close
clinical and ultrasonographic follow-up should be
performed. Repeat FNA can be performed in 6–18
months at the discretion of the clinician.
2. Solid nodules associated with ‘‘nondiagnostic’’ aspi-
rates should be reaspirated with ultrasound guidance
and whenever possible intraprocedural review by a
cytopathologist. If repeat smears are ‘‘nondiag-
nostic,’’ surgery should be strongly considered. If
the patient is considered reliable and likely to return
for clinical follow-up and the nodule is 1 cm or less
in size, close clinical follow-up with ultrasound
examination is a reasonable alternative to surgery.
When growth of the nodule is detected during ultra-
sound surveillance, excision is appropriate.
3. In general, a waiting period of at least 3 months
should elapse between the initial ‘‘nondiagnostic’’
aspirate and reaspiration. If suspicion for a carci-
noma is high based on clinical or ultrasonographic
features, a shorter waiting period may be appropriate
in some patients.
Follow-Up of ‘‘Benign’’ FNA Results
Fine-needle aspirates yielding a diagnosis of ‘‘benign’’
include the categories: nodular goiter, multinodular goiter,
colloid goiter, and Hashimoto’s thyroiditis. The precise
management of these benign and nonneoplastic entities
has varied over time and between institutions. Because
patients with multiple thyroid nodules have the same risk
of malignancy as those with only a single nodule, follow-
up of patients with multiple nodules should be the same
as those with a solitary dominant thyroid nodule. Cytolog-
ically ‘‘benign’’ thyroid nodules require careful clinical
follow-up because up to 5% false-negative rate is associ-
ated with a ‘‘benign’’ cytologic diagnosis.11,12 The false-
negative rate may be higher with FNAs directed by palpa-
tion rather than by ultrasound examination.13,14 Thus,
cytologic diagnoses obtained by palpation directed FNAs
may require closer clinical follow-up than those diagnoses
obtained by ultrasound-guided FNAs. Certain ultrasono-
graphic characteristics indicate a higher likelihood of
malignancy and include microcalcifications, hypoechoge-
nicity in a solid nodule, and intranodular hypervascular-
ity.15,16 These nodules may require more frequent clinical
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and ultrasonographic follow-up after a ‘‘benign’’ diagnosis
is rendered by fine-needle aspiration.
Options for follow-up of ‘‘benign’’ nodules by FNA
have included reaspiration,17 hormone suppressive ther-
apy, and clinical follow-up with repeat ultrasound exami-
nations. Routine medical suppressive therapy to confirm a
‘‘benign’’ cytologic diagnosis remains controversial. Mul-
tiple randomized trials have shown that thyroid hormone
suppression may result in a decrease in nodule size for
patients with borderline low iodine intake. The data are
less convincing in populations ingesting sufficient io-
dine.18–20 Also, rare examples of thyroid hormone sup-
pression of papillary and follicular carcinomas have been
reported. From these data, it is unclear that thyroid hor-
mone suppressive therapy is a reliable test for confirma-
tion of a ‘‘benign’’ cytologic diagnosis of a solitary or
dominant thyroid nodule.
Cytologically ‘‘benign’’ nodules can be followed clini-
cally with repeat ultrasound examination at 6 to 18 month
intervals. These nodules may be reaspirated or surgically
removed when significant change in size occurs. Ultraso-
nography appears to be the best technique for detection of
change in nodule size.21 Unfortunately, there is no general
agreement as to what a significant change in size of a nod-
ule is that necessitates reaspiration or surgical resection.
The ATA has suggested that a 20% increase in nodule di-
ameter with a minimum increase in two or more dimen-
sions of at least 2 mm is a reasonable definition for a sig-
nificant change in nodule size.1 The American Thyroid
Association has recommended clinical follow-up of cytolog-
ically ‘‘benign’’ and easily palpable nodules to occur at 6–
18-month intervals. When nodules are not readily palpable,
the recommendation is for serial ultrasound examination at
6–18-month intervals following the initial ‘‘benign’’ cyto-
logic diagnosis.2 When there is evidence for nodular growth
either by palpation or ultrasonography, repeat FNA should
be performed preferably under ultrasound guidance.2
Conclusions
1. Thyroid nodules cytologically diagnosed as ‘‘be-
nign’’ require careful clinical follow-up. Easily pal-
pable thyroid nodules may be followed clinically at
6–18-month intervals. Nodules that are not readily
palpable should receive serial ultrasound examina-
tions at 6–18-month intervals. The duration of the
follow-up period is not fully defined, but should be
at least 3–5 years following the initial ‘‘benign’’
cytologic diagnosis.
2. If a 20% increase in nodule diameter or a minimum
of a 2-mm increase in two dimensions is detected ei-
ther by palpation or ultrasonography, repeat fine-
needle aspiration is appropriate. Repeat FNA should
also be performed if ultrasound abnormalities (irreg-
ular margins, central hypervascularization) develop.
The repeat fine-needle aspiration should be per-
formed under ultrasound guidance. The attendance
of a cytopathologist at the reaspiration procedure is
optimal to assess sample adequacy.
3. At this time, hormone suppressive therapy cannot be
recommended as a diagnostic maneuver for confir-
mation of benignancy in a cytologically ‘‘benign’’
thyroid nodule.
4. Ethanol ablation may be considered in selected
patients.
Follow-Up of ‘‘Atypical/Borderline’’ FNA Results
A variety of terms are employed by laboratories to con-
vey uncertainty about the significance of thyroid cytologic
findings. Such changes do not rise to the level of a signif-
icant concern for a follicular neoplasm meriting lobec-
tomy (see below), nor do they fit a ‘‘suspicious for malig-
nancy’’ interpretation (see later). Because of some (usu-
ally focal and/or mild) cytologic or architectural atypia,
neither can such cases be reliably called benign. A variety
of diagnostic headings are used to report such cases.
These include ‘‘atypical follicular lesion,’’ ‘‘cellular follic-
ular lesion,’’ and ‘‘indeterminate.’’ (The term ‘‘indeter-
minate’’ has also been used by some laboratories to mean
‘‘follicular neoplasm’’ as discussed in the next section.)
The term ‘‘atypical/borderline’’ will be used for the re-
mainder of this discussion. For additional discussion, see
the accompanying article in this issue by Baloch et al.1
The lack of agreement on terminology for this category
has led to variability in the percentage of these lesions
which are malignant. In a majority of series, *5–10% of
the ‘‘atypical/borderline’’ category are malignant neo-
plasms with the remaining 90–95% being adenomas or
dominant nodules of a multinodular goiter.22,23 Other
authors have reported a 20–30% malignancy rate.24–26
Given that this diagnostic category is associated with low
specificity and a low positive predictive value, the appro-
priate follow-up or therapy for the category remains con-
troversial. Some authorities have recommended repeat
FNAs, repeat ultrasound scans, or radionucleotide uptake
studies. A repeat FNA is benign in about one-half of
patients, obviating the need for surgery.27 Some reports
have even suggested the use of liquid-based cytology and
immunocytochemistry to improve diagnostic accuracy.28–34
Radiological correlation may also be helpful in improv-
ing the overall positive predictive value of the ‘‘atypical/
borderline’’ category. Besides increasing size, ultrasono-
graphic features such as hypoechogenicity, irregular nodu-
lar border, calcifications, and abnormalities of vasculariza-
tion all favor a malignant diagnosis.35,36
Although no consensus has been reached concerning
the value of iodine-123 scans, it may be useful in selected
cases. In cases cytologically designated as ‘‘atypical/bor-
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derline,’’ and when the serum TSH level is low or below
normal the referring clinician may consider an iodine-123
scan. If the scan is ‘‘hot,’’ clinical follow-up with a repeat
FNA in 3–6 months is appropriate. If the scan is ‘‘cold,’’
the patient may be referred for surgery. In patients who
are suboptimal operative candidates, close clinical follow-
up with repeat ultrasound to detect an increase in nodule
size, abnormalities of vascularization or the presence of
calcification can be performed to increase the diagnostic
accuracy of the ‘‘atypical/borderline’’ category.
The utility of outside ‘‘expert’’ consultation is debata-
ble, but in some patients where reaspiration is not easily
attainable, expert consultation may be a reasonable alter-
native to reaspiration or surgery.
Conclusions
1. Outside expert cytopathology consultation may be
considered in cases with an ‘‘atypical/borderline’’
cytologic diagnosis.
2. In general, a conservative approach is recommended.
After a single ‘‘atypical/borderline’’ interpretation, a
repeat FNA should be considered in 3–6 months. If
the repeat FNA is ‘‘atypical/borderline’’ or worse, a
surgical consultation should be considered.27
Follow-Up of an FNA Diagnosis of
‘‘Follicular Neoplasm’’
This category has in some reports been termed ‘‘Suspi-
cious for Follicular Neoplasm.’’24–27,35 The category of
‘‘Neoplasm’’ generally refers to follicular neoplasms with
the majority being adenomas. The category is associated
with a 20–30% incidence of malignancy.2,22,24–26 Because
of the high incidence of malignancy associated with this
diagnostic category, operative intervention has been
recommended.2
Conclusions
1. Patients with a diagnosis of ‘‘follicular neoplasm’’ or
‘‘suspicious for follicular neoplasm’’ should be
referred to a surgeon for operative exploration. Usu-
ally, a lobectomy is performed followed by histo-
logic examination of the lesion for capsular and/or
vascular invasion. In some cases, total thyroidec-
tomy may be performed. The choice between lobec-
tomy and total thyroidectomy depends on a variety
of factors including the presence or absence of nod-
ules in the contralateral lobe and the characteristics
of the index nodule combined with the age of the
patient.
2. There is little support in the literature for frozen sec-
tion evaluation to intraoperatively separate follicular
adenomas from follicular carcinomas. If capsular or
vascular invasion is documented, total thyroidec-
tomy may be performed. When capsular or vascular
invasion is not identified, the operation may be com-
pleted by lobectomy.
3. When frozen section is not utilized, the initial sur-
gery is usually limited to lobectomy. If subsequent
histologic examination discloses capsular or vascular
invasion, the diagnosis follicular carcinoma is made.
Depending on the discretion of the surgeon, the his-
topathologic characteristics of the carcinoma and the
clinical status of the patient, reoperation and total
thyroidectomy may be performed.2
Follow-Up of FNAs With a Diagnosis of
‘‘Suspicious for Malignancy’’
In the majority of cases where this category is used, the
cytopathologist is concerned that the nodule may repre-
sent a papillary carcinoma, but insufficient criteria are
present for a definitive diagnosis.22 Less commonly, other
malignancies such as medullary carcinoma are included in
this category. Approximately 50–75% of the lesions
placed in this category are malignant.22,27
Conclusions
Patients with an FNA diagnosis of ‘‘suspicious for malig-
nancy’’ should be referred to a surgeon for consideration
of thyroid lobectomy. Subsequent operative intervention
depends on intraoperative or postoperative histologic
review. Intraoperative frozen section may be of significant
aid in determining the extent of surgery when a definitive
diagnosis of papillary carcinoma is made by frozen sec-
tion evaluation. Because of an increased risk of malig-
nancy in this category, total thyroidectomy should be con-
sidered in patients with large tumors (>4 cm), when
marked atypia is seen on FNA and in patients with a fam-
ily or personal history of radiation exposure. Patients with
bilateral nodular disease or those who prefer to undergo
bilateral thyroidectomy to avoid the possibility of future
thyroid surgery on the contralateral lobe should be consid-
ered for total thyroidectomy.2
Follow-Up of ‘‘Malignant’’ FNA Results
This category refers to the histopathologic entities of pap-
illary carcinoma, medullary carcinoma, lymphoma, and
anaplastic carcinoma. Little controversy exists that a posi-
tive cytologic diagnosis of malignancy in a thyroid nodule
should be followed by a referral for surgery. In many
cases, a definitive type of carcinoma can and should be
cytologically diagnosed. Controversy exists as to the opti-
mal surgical therapy for papillary carcinoma. The decision
to perform lobectomy or total thyroidectomy is at the dis-
cretion of the surgeon and depends on a number of factors
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including size and subtype of papillary carcinoma, patient
age and patient health status. The ATA recommends total
or near total thyroidectomy if any of the following fea-
tures are present: primary carcinoma is more than 1–1.5
cm in size, contralateral thyroid nodules are present, re-
gional or distant metastases are present, patient history of
radiation to head or neck or a first degree relative with
differentiated carcinoma of the thyroid. Patient age over
40 may also favor total thyroidectomy. However, if the
cytology suggests metastatic cancer, a search to identify
the primary site is required so that unnecessary thyroidec-
tomy is avoided. The most common metastatic tumors are
renal cell carcinoma, metastatic carcinoma of the lung
and metastatic adenocarcinoma of the breast.
Conclusions
1. The cytologic diagnosis of malignancy in the thyroid
nodule should result in the referral of the patient for
surgical consultation.
2. Whenever possible, the type of carcinoma present
should be stated in the cytologic diagnosis.
3. It is mandatory that metastatic carcinoma be
excluded whenever possible before surgical interven-
tion is undertaken.
4. In certain clinical situations, surgical intervention
may initially be simple lobectomy or lobectomy
with intraoperative frozen section examination to
determine if total thyroidectomy should be per-
formed. When frozen section examination confirms
the presence of a primary thyroid carcinoma, total
thyroidectomy may be performed.2 If frozen section
is equivocal, the operative procedure is ended with a
lobectomy, and further therapy is based on the find-
ings of permanent sections.2
5. Depending on the patient’s clinical status and the
characteristics of the malignancy, total thyroidec-
tomy may be performed for a cytologic diagnosis of
papillary carcinoma.
6. Controversy exists as to whether total thyroidectomy
or unilateral lobectomy should be performed in
some cases of papillary carcinoma. The selection of
lobectomy versus thyroidectomy depends on the
evaluation of the patient’s clinical status and the
size and nature of the papillary carcinoma present.
Papillary carcinomas under 1–1.5 cm in size and
without unfavorable prognostic features may best be
treated by simple lobectomy. Larger carcinomas and
especially those over 4 cm in size should, in most
cases, undergo total or near total thyroidectomy.
7. If total thyroidectomy is performed, it may be
accompanied by a central compartment dissection.
For patients with large bulky disease or recurrent la-
ryngeal nerve dysfunction, preoperative cross-sec-
tional imaging should be considered as well as ultra-
sound imaging for lateral neck nodal disease.
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